The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1200/JCO.2012.43.2674

PMID

23071247

PICO

Population

Adult patients with anaplastic oligodendroglioma (AO) or anaplastic oligoastrocytoma (AOA), Karnofsky performance status ≥60.

Intervention

Intensive procarbazine, lomustine, and vincristine (PCV) chemotherapy followed by involved-field radiotherapy (RT).

Comparator

Radiotherapy (RT) alone.

Outcomes

Overall survival (primary), progression-free survival, survival by 1p/19q codeletion status.

Design

Type

Phase III randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

Not blinded

Follow-up

Long-term (median survival up to 14.7 years in subgroups)

Primary endpoint

Overall survival (OS)

Secondary endpoints

Progression-free survival
Survival stratified by 1p/19q codeletion status

Practice impact

What this means

This phase III RCT compared PCV chemotherapy plus RT vs RT alone in anaplastic oligodendroglioma. While no OS benefit was seen in the entire cohort, patients with 1p/19q codeleted tumors had doubled median survival with PCV+RT (14.7 vs 7.3 years). However, this key finding comes from an unplanned subgroup analysis. For codeleted tumors, consider PCV+RT, but temozolomide-based regimens are now more common.

Bottom line

PCV plus RT improves survival in 1p/19q codeleted anaplastic oligodendrogliomas, but benefit is based on unplanned subgroup analysis.

Strength of evidence

moderate

Recommendation

consider change

Why it matters

Significant survival benefit in codeleted subset (HR 0.59, P=0.03).
Adjusted analysis shows OS benefit for all patients (HR 0.67, P=0.01).
Limitation: codeleted subgroup analysis was unplanned.

What would change my mind

Randomized trial comparing PCV+RT vs temozolomide+RT in codeleted tumors.
Validation of survival benefit in prospective trial with codeletion as stratification factor.
Long-term toxicity data showing PCV outweighs benefit.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Low risk: randomized, permuted block design, central pathology review, intention-to-treat analysis.

Confounding

Stratified by age, KPS, and anaplasia grade; Cox models adjusted for codeletion status.

Missing data

Minimal: 291 eligible patients analyzed; codeletion data available for most but not all (subgroup analysis).

Multiplicity

Multiple subgroup analyses (codeleted vs noncodeleted) increase risk of type I error; key survival benefit in codeleted subset from unplanned analysis.

Notes

Codeletion analysis was unplanned and retrospective.
No temozolomide comparator.

Stats check

NNT

Not reported

Effect sizes

HR 0.79 (95% CI 0.60-1.04) for OS in entire cohort
HR 0.59 (95% CI 0.37-0.95) for OS in codeleted tumors with PCV+RT vs RT
HR 0.67 (95% CI 0.50-0.91) for adjusted OS with PCV+RT

Absolute effects

Median survival 4.6 years for PCV+RT vs 4.7 years for RT in entire cohort
Median survival 14.7 years for PCV+RT vs 7.3 years for RT in codeleted tumors
291 eligible patients randomized

Concerns

Primary endpoint (OS in entire cohort) not statistically significant (P=0.1).
Key finding in codeleted subset from unplanned analysis.

External validity

Who it applies to

Adult patients with newly diagnosed AO/AOA, especially those with 1p/19q codeleted tumors.

Who it does not

Patients with noncodeleted tumors (no survival benefit from PCV), pediatric populations, those receiving temozolomide.

Generalizability notes

Multicenter trial (76 centers) enhances generalizability.
PCV regimen used is intensive and may have higher toxicity than temozolomide.

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.multiplicity

locator

p. 2 Results

quote

For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.

claim_id

stats_check.effect_sizes

locator

p. 2 Results

quote

median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03)

claim_id

practice_impact.rationale

locator

p. 2 Results

quote

In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01)

Metadata

Generated at

2026-03-06T13:41:29.251Z

Version

top 100 cited in past 20 years